2. Search Result
Search Result
Results for "

sodium-glucose

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

2

Natural
Products

1

Recombinant Proteins

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-109144
    Enavogliflozin

    DWP-16001

    		 SGLT Metabolic Disease
    Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor .
    Enavogliflozin
  • HY-128723
    Dapagliflozin impurity

    		SGLT Others
    Dapagliflozin impurity is an enantiomer of Dapagliflozin which is a sodium-glucose transporter 2 inhibitor .
    Dapagliflozin impurity
  • HY-109018
    Velagliflozin
    1 Publications Verification

    		 SGLT Metabolic Disease
    Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.
    Velagliflozin
  • HY-116223
    Tianagliflozin

    		SGLT Metabolic Disease
    Tianagliflozin is a sodium/glucose cotransporter 2 (SGLT-2) inhibitor with potential for investigation in type 2 diabetes .
    Tianagliflozin
  • HY-13414
    Remogliflozin

    Remogliflozin A

    		 SGLT Metabolic Disease
    Remogliflozin is a potent and selective inhibitor of SGLT2 (sodium-glucose cotransporter 2) with Kis of 12.4 and 26 nM for human and rat SGLT2, respectively. Remogliflozin is the active form of Remogliflozin etabonate(HY-14945) .
    Remogliflozin
  • HY-109018A
    Velagliflozin proline
    1 Publications Verification

    		 SGLT Metabolic Disease
    Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
    Velagliflozin proline
  • HY-14902
    Tofogliflozin

    CSG452

    		 SGLT Metabolic Disease
    Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.
    Tofogliflozin
  • HY-153113
    Rongliflozin

    DJT1116PG

    		 SGLT Endocrinology
    Rongliflozin (DJT1116PG) is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2). Rongliflozin can be used for the research of type 2 diabetes mellitus (T2DM) .
    Rongliflozin
  • HY-123011
    Henagliflozin

    SHR3824

    		 SGLT Metabolic Disease
    Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC50 values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research .
    Henagliflozin
  • HY-122613
    YM543 free base

    		SGLT Metabolic Disease
    YM543 free base is a potent and orally active sodium-glucose cotransporter (SGLT) 2 inhibitor. YM543 free base reduces blood glucose levels. YM543 free base can be used in research of diabetes .
    YM543 free base
  • HY-10449A
    Luseogliflozin hydrate

    TS 071 hydrate

    		 SGLT Metabolic Disease
    Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM) .
    Luseogliflozin hydrate
  • HY-109018B
    Velagliflozin proline hydrate

    		SGLT Metabolic Disease
    Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
    Velagliflozin proline hydrate
  • HY-10450
    Dapagliflozin
    Maximum Cited Publications
    31 Publications Verification

    BMS-512148

    		 SGLT Metabolic Disease Cancer
    Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .
    Dapagliflozin
  • HY-13413
    Tofogliflozin (hydrate)
    4 Publications Verification

    CSG-452 hydrate

    		 SGLT Reactive Oxygen Species Metabolic Disease
    Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific sodium/glucose cotransporter 2 (SGLT2) inhibitor with an IC50 of 2.9 nM and Ki values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse SGLT2 . Tofogliflozin partially inhibits high glucose-induced reactive oxyen species (ROS) generation in tubular cells .
    Tofogliflozin (hydrate)
  • HY-N0142
    Phloretin
    10+ Cited Publications

    NSC 407292; RJC 02792

    		 SGLT Endogenous Metabolite GLUT Metabolic Disease Cancer
    Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC50values of 49 μM and 61 μM, respectively .Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation .
    Phloretin
  • HY-10450A
    Dapagliflozin ((2S)-1,2-propanediol, hydrate)
    Maximum Cited Publications
    31 Publications Verification

    BMS-512148 (2S)-1,2-propanediol, hydrate

    		 SGLT Metabolic Disease Cancer
    Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury .
    Dapagliflozin ((2S)-1,2-propanediol, hydrate)
  • HY-N0142R
    Phloretin (Standard)

    NSC 407292 (Standard); RJC 02792 (Standard)

    		 SGLT Endogenous Metabolite GLUT Metabolic Disease Cancer
    Phloretin (Standard) is the analytical standard of Phloretin. This product is intended for research and analytical applications. Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC50values of 49 μM and 61 μM, respectively .Phloretin has the potential for the treatment of rheumatoid arthritis (RA)?and allergic airway inflammation .
    Phloretin (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: